HER3 Rationale Text Module

CME

Expanding Our Understanding of HER3 Expression, Implications, and Rationale for HER3-Targeted Therapy in Solid Tumors

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: October 20, 2023

Expiration: October 19, 2024

Misako Nagasaka
Misako Nagasaka, MD, PhD

Activity

Progress
1 2
Course Completed

Introduction

In this module, Misako Nagasaka, MD, PhD, explains the biology of HER3 overexpression and the rationale for targeting HER3 in the treatment of solid tumors. This includes information on the physiologic function of the ERBB/HER tyrosine kinase family and the role of HER3 in oncogenic signaling and acquired resistance to targeted therapies in several cancer types. 

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A question will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your response will be aggregated for analysis, and your specific response will not be shared.
Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with cancer do you provide care for in a typical week?

For those providing patient care, on which of the following tumor types does your clinical practice focus?

Current evidence indicates that HER3 activation primarily drives oncogenic signaling through which of the following pathways?